TY - JOUR
T1 - Natriuretic Peptides in Chronic Heart Failure
AU - Brunner-La Rocca, Hanspeter
AU - Sanders - van Wijk, Sandra
N1 - Funding Information:
Disclosure: Both authors receive unrestricted research grants from Roche Diagnostics. Received: 31 July 2018 Accepted: 4 January 2019 Citation: Cardiac Failure Review 2019;5(1):44–9. DOI: https://doi.org/10.15420/cfr.2018.26.1 Correspondence: HP Brunner-La Rocca, Department of Cardiology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, the Netherlands. E: hp.brunnerlarocca@mumc.nl Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
Publisher Copyright:
© RADCLIFFE CARDIOLOGY 2018
PY - 2019
Y1 - 2019
N2 - Normal brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels are helpful in excluding chronic heart failure in the ambulatory setting, although they have been studied less well and possibly less accurately than in acute care. They may also be of help in screening patients at risk to intervene and reduce the development of heart failure. Natriuretic peptides are also excellent prognostic markers of chronic heart failure, but the clinical value of such prognostic information is less clear. One possible application for this information is guiding medical therapy in chronic heart failure. Many studies have investigated this approach, but results are mixed and do not clearly show improvement in outcome. Still, it may be that in patients with reduced ejection fraction and few comorbidities, measuring NT-proBNP to uptitrate medication improves prognosis.
AB - Normal brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels are helpful in excluding chronic heart failure in the ambulatory setting, although they have been studied less well and possibly less accurately than in acute care. They may also be of help in screening patients at risk to intervene and reduce the development of heart failure. Natriuretic peptides are also excellent prognostic markers of chronic heart failure, but the clinical value of such prognostic information is less clear. One possible application for this information is guiding medical therapy in chronic heart failure. Many studies have investigated this approach, but results are mixed and do not clearly show improvement in outcome. Still, it may be that in patients with reduced ejection fraction and few comorbidities, measuring NT-proBNP to uptitrate medication improves prognosis.
U2 - 10.15420/cfr.2018.26.1
DO - 10.15420/cfr.2018.26.1
M3 - Article
SN - 2057-7540
VL - 5
SP - 44
EP - 49
JO - Cardiac Failure Review
JF - Cardiac Failure Review
IS - 1
ER -